MALAT1 silencing suppresses prostate cancer progression by upregulating miR-1 and downregulating KRAS

Background Prostate cancer (PC) is the second leading cause of cancer-related deaths among men. Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) performed as an oncogene in multiple cancers including PC. However, the molecular mechanisms of MALAT1 implicated in PC progression have not been thoroughly elaborated. Materials and methods Reverse transcription-quantitative polymerase chain reaction assay was used to detect the expressions of MALAT1 and microRNA-1 (miR-1). Protein levels of cleaved poly (ADP-ribose) polymerase, cleaved caspase-3, BAX, bcl-2, and KRAS were determined using a western blot assay. Cell proliferation was assessed by colony formation and MTS assays. Cell migration capacity was examined by transwell migration assay (Corning Incorporated, Corning, NY, USA). Apoptosis rate was measured by flow cytometry via double staining of annexin V-FITC and propidium iodide. Luciferase and RNA immunoprecipitation assays were employed to explore the relationship among miR-1, MALAT1, and KRAS. Results MALAT1 expression was upregulated and miR-1 expression was downregulated in PC tissues and cell lines. MALAT1 knockdown inhibited cell proliferation and migration, and promoted cell apoptosis in androgen receptor-negative DU145 and PC3 cells. Molecular mechanism explorations disclosed that MALAT1 acted as a molecular sponge of miR-1 in DU145 cells. Moreover, miR-1 downregulation partly abrogated MALAT1 silencing-mediated anti-proliferative, antimigratory, and proapoptotic effects in DU145 and PC3 cells. Further investigation revealed that KRAS was a target of miR-1 in DU145 cells. MALAT1 acted as a competing endogenous RNA of miR-1, resulting in the increase of KRAS expression in DU145 and PC3 cells. Furthermore, miR-1 overexpression hampered proliferation and migration and promoted apoptosis in DU145 and PC3 cells, while these effects were markedly weakened following KRAS upregulation. Conclusion MALAT1 knockdown inhibited proliferation and migration and facilitated apoptosis by upregulating miR-1 and downregulating KRAS in androgen receptor-negative PCa cells, providing a new insight into the molecular basis of MALAT1 and a potential biomarker or therapeutic target for suppressing castration-resistant PC.

[1]  Timothy J Wilt,et al.  Prevention and early detection of prostate cancer. , 2014, The Lancet. Oncology.

[2]  A. De Siervi,et al.  Implications of microRNA dysregulation in the development of prostate cancer. , 2017, Reproduction.

[3]  Jie Li,et al.  Hsa-miR-1 suppresses breast cancer development by down-regulating K-ras and long non-coding RNA MALAT1. , 2015, International journal of biological macromolecules.

[4]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[5]  Channing J Der,et al.  KRAS: feeding pancreatic cancer proliferation. , 2014, Trends in biochemical sciences.

[6]  N. Seki,et al.  Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer , 2011, British Journal of Cancer.

[7]  N. Seki,et al.  The functional significance of miR-1 and miR-133a in renal cell carcinoma. , 2012, European journal of cancer.

[8]  S. Diederichs,et al.  MALAT1 — a paradigm for long noncoding RNA function in cancer , 2013, Journal of Molecular Medicine.

[9]  W. Catalona,et al.  Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). , 2009, Urologic oncology.

[10]  Hongwei Liang,et al.  miR‐1 suppresses the proliferation and promotes the apoptosis of esophageal carcinoma cells by targeting Src , 2017, Cancer medicine.

[11]  M. Burchardt,et al.  MicroRNA-1 properties in cancer regulatory networks and tumor biology. , 2016, Critical reviews in oncology/hematology.

[12]  R. Stephens,et al.  MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer , 2011, Nucleic acids research.

[13]  Q. Kan,et al.  Regulation of microRNA-1 (miR-1) expression in human cancer. , 2017, Biochimica et biophysica acta. Gene regulatory mechanisms.

[14]  Cheng Huang,et al.  Long Noncoding RNA MALAT1: Insights into its Biogenesis and Implications in Human Disease. , 2015, Current pharmaceutical design.

[15]  Rui Yang,et al.  Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer , 2015, Tumor Biology.

[16]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[17]  A. Stojadinovic,et al.  Current Approaches, Challenges and Future Directions for Monitoring Treatment Response in Prostate Cancer , 2014, Journal of Cancer.

[18]  S. Dhanasekaran,et al.  Characterization of KRAS rearrangements in metastatic prostate cancer. , 2011, Cancer discovery.

[19]  Yan Zhang,et al.  MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR-1 with cdc42. , 2016, Biochemical and biophysical research communications.

[20]  Q. Lu,et al.  Reciprocal regulation of Hsa-miR-1 and long noncoding RNA MALAT1 promotes triple-negative breast cancer development , 2016, Tumor Biology.

[21]  K. Takayama,et al.  Long non‐coding RNAs and prostate cancer , 2017, Cancer science.

[22]  Rosalie Nolley,et al.  The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? , 2004, The Journal of urology.

[23]  Xiaoqi Liu,et al.  MicroRNAs in prostate cancer: Functional role as biomarkers. , 2017, Cancer letters.

[24]  A. Partin,et al.  Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer , 2015, Prostate Cancer and Prostatic Disease.

[25]  Artemis G Hatzigeorgiou,et al.  Analyzing MiRNA-LncRNA Interactions. , 2016, Methods in molecular biology.

[26]  S. Varambally,et al.  Prostate Cancer Imaging and Biomarkers Guiding Safe Selection of Active Surveillance , 2017, Front. Oncol..

[27]  M. Esteller,et al.  lncRNAs and microRNAs with a role in cancer development. , 2016, Biochimica et biophysica acta.

[28]  H. Miyake,et al.  Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches , 2013, International journal of urology : official journal of the Japanese Urological Association.

[29]  W Abou-Kheir,et al.  MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms , 2013, Oncogene.

[30]  J. Hou,et al.  Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. , 2013, The Journal of urology.

[31]  Jingxuan Shi,et al.  miR‐1, regulated by LMP1, suppresses tumour growth and metastasis by targeting K‐ras in nasopharyngeal carcinoma , 2015, International journal of experimental pathology.

[32]  F. Zhang,et al.  Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation , 2012, Medical Oncology.

[33]  J. Mattick,et al.  Non‐coding RNAs: regulators of disease , 2010, The Journal of pathology.

[34]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[35]  Robert A. Weinberg,et al.  Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.

[36]  Jiří Drábek,et al.  Clinical Relevance of KRAS in Human Cancers , 2010, Journal of biomedicine & biotechnology.

[37]  Yong Wang,et al.  Long non-coding RNA MALAT1 for promoting metastasis and proliferation by acting as a ceRNA of miR-144-3p in osteosarcoma cells , 2017, Oncotarget.

[38]  George A. Calin,et al.  Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer , 2017, International journal of molecular sciences.

[39]  D. Bonci,et al.  MicroRNA as New Tools for Prostate Cancer Risk Assessment and Therapeutic Intervention: Results from Clinical Data Set and Patients' Samples , 2014, BioMed research international.

[40]  P. Pandolfi,et al.  The multilayered complexity of ceRNA crosstalk and competition , 2014, Nature.